Your most frequent questions

Non-invasive prenatal testing (NIPT) is an innovative genetic test offered to pregnant women in cases where there is a risk of trisomies 13, 18 and 21 in the foetus. It can be performed using a sample of the mother’s blood from 10 weeks (gestational age), which is equivalent to being eight weeks pregnant right after ultrasound.

This test can now also screen for other chromosomal abnormalities and chromosomal imbalances.

It is rapid, reliable and safe, and enables the detection of trisomies 13, 18 and 21, while limiting the number of invasive samples, such as amniocentesis or chorionic villus sampling.

The test is recommended for pregnant women at high risk of trisomies 13, 18 and 21. You should ask your healthcare professional (e.g. doctor, midwife, genetic counsellor), who will advise you on whether or not it is necessary to perform a NIPT test based on your clinical status.

Your healthcare professional will answer your question. Please reach out to them.

Ninalia NIPT can be performed at any point in the pregnancy from Week 10 (gestational age).

Non-invasive prenatal testing for trisomies 13, 18 and 21 is recommended for pregnant women found to be at high risk following standard screening using maternal serum markers and who do not wish to undergo an invasive procedure (e.g. amniocentesis, chorionic villus sampling) as first-line testing.

The results are reported directly to the healthcare professional who prescribed the test within a period of five business days (Monday-Friday) upon receipt of the sample at Eurofins Biomnis.

A positive result indicates a strong suspicion that the foetus is affected by one of the anomalies being investigated (trisomies 21, 18 and 13). Your doctor will tell you which additional tests need to be conducted in order to confirm the diagnosis.
Autosomal aneuploidies and chromosomal imbalance are rare chromosomal abnormalites. In cases of a positive result, your healthcare professional will explain the care best suited to you.

A negative result indicates a very low risk that the foetus is affected by one of the anomalies being investigated (trisomies 13, 18 and 21). Your doctor will tell you if it is necessary to perform other tests in addition to medical follow-ups and “standard” ultrasound monitoring of your pregnancy.

Since October 2014, Eurofins Biomnis has chosen to collaborate with the company Illumina, a world leader in DNA sequencing, for non-invasive screening for the main chromosomal abnormalities.

The new VeriSeq NIPT method offers the best performance currently available, in terms of sensitivity, specificity, and detection rate, etc. for non-invasive prenatal testing.

Detection rate for trisomy 21, 18 and 13 is > 99,9%

Over 250,000 Ninalia tests have been performed to date.

Your blood sample is sent to Eurofins Biomnis in France.

The sample for Ninalia NIPT is based on a single blood collection, which is safe for both you and your foetus.
The blood sample can be collected directly at your physician’s office or by a Eurofins Biomnis partner.
Your healthcare provider will then send your sample to Eurofins Biomnis for them to perform the test.

The doctor monitoring your pregnancy is familiar with your medical file. They can answer your questions. Feel free to ask them for advice.

Eurofins Biomnis is authorised by the Regional Health Authority to perform prenatal diagnostics and has all of the licences necessary to conduct this genetic test.

European leader in the sector of specialised medical pathology, Eurofins Biomnis carries out over 39,000 analyses per day from a range of over 3,000 available tests, including specialised tests for which the company has the appropriate authorisations.

Founded in 1897 by Marcel Mérieux, Eurofins Biomnis remains the leader in the field of specialised medical pathology in France. It has kept its position through continuous technological innovation and investment, particularly in areas such as female biology, oncology and personalised medicine, as well as chromosomal and molecular genetics.

With 125 years of expertise and innovation in the service of medical pathology, Eurofins Biomnis is the core of the Eurofins Clinical Diagnostics division in Europe and has plans for international development.